|
시장보고서
상품코드
2061450
계란 유래 포스파티딜콜린 시장 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)Egg Phosphatidylcholine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035 |
||||||
세계의 계란 유래 포스파티딜콜린 시장은 2025년에 3억 달러로 평가되고 CAGR 6.5%로 성장하며, 2035년까지 5억 6,310만 달러에 달할 것으로 예측됩니다.
의약품, 뉴트라슈티컬, 화장품 제제 분야에서 천연 유래 인지질의 활용이 확대됨에 따라 해당 시장은 성장세를 보이고 있습니다. 계란 유래 포스파티딜콜린은 달걀 노른자에서 추출되며, 생체 세포막의 주요 구성 성분으로 알려져 있습니다. 레시틴의 일종으로, 양성 분자의 성질을 나타내며, 수성 환경과 지질 환경 모두와 상호작용할 수 있습니다. 이러한 특성으로 인해 제제 과학 분야에서 유화제, 안정제, 운반 분자로서 매우 뛰어난 효과를 발휘합니다. 이러한 높은 순도 프로필과 뛰어난 생체 이용률은 천연 지질계 원료를 찾는 제조사들 사이에서 이 성분에 대한 수요를 높이고 있습니다. 또한 달걀에서 유래한 포스파티딜콜린은 간 기능, 신경계 발달, 세포 신호 전달 과정을 돕는 콜린의 중요한 식이 공급원 역할도 합니다. 생체 시스템과의 친화성 덕분에 지질 나노입자 전달 시스템이나 첨단 의약품 제형에서의 사용이 증가하고 있으며, 여러 최종 용도 부문에서 그 산업적 중요성이 크게 확대되고 있습니다.
| 시장 범위 | |
|---|---|
| 시작연도 | 2025년 |
| 예측 기간 | 2026-2035년 |
| 개시 금액 | 3억 달러 |
| 예측 시장 규모 | 5억 6,310만 달러 |
| CAGR | 6.5% |
2025년, 분말 형태 부문은 1억 9,500만 달러를 차지했습니다. 분말 형태의 계란 유래 포스파티딜콜린은 안정성 향상, 유통기한 연장, 건조 제형 시스템에 대한 배합 용이성 등으로 인해 널리 선호되고 있습니다. 이는 일관된 취급과 보관 효율이 요구되는 용도에 특히 적합합니다. 한편, 과립 형태의 제품도 유동성이 향상되고 분진 발생이 줄어들어 대규모 생산 및 가공 환경에서 더 효율적이기 때문에 채택이 증가하고 있습니다.
의약품 부문은 2025년에 1억 4,400만 달러의 시장 규모를 기록했습니다. 이 부문의 수요는 첨단 약물전달 시스템, 특히 지질 나노입자 제제 및 주사제의 광범위한 사용에 힘입어 증가하고 있습니다. 이러한 높은 생체적합성과 생체이용률을 높이는 능력 덕분에, 현대의 의약품 개발에서 선호되는 첨가제로 자리 잡고 있습니다. 혁신적인 치료용 제제에 대한 적용이 확대됨에 따라 임상 및 생의학적 용도에서의 그 역할은 계속해서 강화되고 있습니다.
북미의 계란 유래 포스파티딜콜린 시장은 2025년 9,850만 달러에서 2035년에는 1억 8,160만 달러로 성장할 것으로 전망됩니다. 이러한 지역적 성장은 활발한 의약품 혁신 활동, 건강기능식품에 대한 수요 증가, 식품 및 퍼스널 케어 산업 전반에 걸친 클린 라벨 원료에 대한 선호도 상승에 힘입어 이루어지고 있습니다. 이러한 요인들이 복합적으로 작용하여, 여러 최종 용도 부문에서 계란 유래 포스파티딜콜린을 기반으로 한 제품의 채택이 꾸준히 확대되고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 개요
제3장 산업 인사이트
제4장 경쟁 구도
제5장 시장 추정·예측 : 형태별, 2022-2035년
제6장 시장 추정·예측 : 순도 등급별, 2022-2035년
제7장 시장 추정·예측 : 용도별, 2022-2035년
제8장 시장 추정·예측 : 지역별, 2022-2035년
제9장 기업 개요
KSA 26.06.24The Global Egg Phosphatidylcholine Market was valued at USD 300 million in 2025 and is estimated to grow at a CAGR of 6.5% to reach USD 563.1 million by 2035.
The market is gaining traction due to rising utilization of naturally derived phospholipids in pharmaceutical, nutraceutical, and cosmetic formulations. Egg phosphatidylcholine is extracted from egg yolk and is recognized as a key structural component of biological cell membranes. As part of the lecithin family, it exhibits amphiphilic properties, enabling it to interact with both aqueous and lipid environments. This characteristic makes it highly effective as an emulsifier, stabilizing agent, and carrier molecule in formulation science. Its high purity profile and strong bioavailability are increasing its preference among manufacturers seeking natural lipid-based ingredients. In addition, it serves as an important dietary source of choline, which supports liver function, neurological development, and cellular signaling processes. Its compatibility with biological systems has led to growing use in liposomal delivery systems and advanced drug formulations, significantly expanding its industrial relevance across multiple end-use sectors.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $300 Million |
| Forecast Value | $563.1 Million |
| CAGR | 6.5% |
The powder form segment accounted for USD 195 million in 2025. Powdered egg phosphatidylcholine is widely preferred due to its enhanced stability, longer shelf life, and ease of incorporation into dry formulation systems. It is particularly suitable for applications requiring consistent handling and storage efficiency. Meanwhile, granular variants are also witnessing increased adoption, supported by their improved flow characteristics and reduced dust generation, making them more efficient for large-scale production and processing environments.
The pharmaceuticals segment generated USD 144 million in 2025. Demand within this segment is driven by extensive use in advanced drug delivery systems, particularly liposomal formulations and injectable therapies. Its high biocompatibility and ability to enhance bioavailability make it a preferred excipient in modern pharmaceutical development. Growing adoption in innovative therapeutic formulations continues to strengthen its role in clinical and biomedical applications.
North America Egg Phosphatidylcholine Market is projected to grow from USD 98.5 million in 2025 to USD 181.6 million in 2035. Regional expansion is supported by strong pharmaceutical innovation activity, rising demand for dietary supplements, and increasing preference for clean-label ingredients across the food and personal care industries. These factors collectively contribute to the steady adoption of egg phosphatidylcholine-based products across multiple end-use sectors.
Key companies operating in the Global Egg Phosphatidylcholine Market include Lipoid GmbH, VAV Life Sciences Pvt. Ltd., Avanti Polar Lipids (Croda International), Phospholipid GmbH, American Lecithin Company, Amadis Chemical Company Limited, Kewpie Corporation, Shaanxi Dideu Medichem Co., Ltd., Doosan Corporation, and Guangzhou Hanfang Pharmaceutical Company Limited. Companies operating in the egg phosphatidylcholine market are focusing on strengthening their position through continuous investment in high-purity extraction technologies and advanced purification processes to improve product consistency and bioavailability. They are expanding production capacities to meet rising demand from the pharmaceutical and nutraceutical industries while ensuring compliance with strict quality standards. Strategic collaborations with drug formulation developers and research institutions are supporting innovation in liposomal drug delivery systems. Manufacturers are also prioritizing portfolio diversification by developing multiple grades and forms suited for specific applications such as injectables and dietary supplements.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope and definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Data mining sources
- 1.3.1 Global
- 1.3.2 Regional/Country
- 1.4 Base estimates and calculations
- 1.4.1 Base year calculation
- 1.4.2 Key trends for market estimation
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.6 Forecast model
- 1.7 Research assumptions and limitations
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
- 2.2 Key market trends
- 2.2.1 Form
- 2.2.2 Purity
- 2.2.3 Application
- 2.2.4 Regional
- 2.3 TAM Analysis, 2026-2035
- 2.4 CXO perspectives: Strategic imperatives
- 2.5 Future outlook and strategic recommendations
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.1.1 Supplier landscape
- 3.1.2 Profit margin
- 3.1.3 Value addition at each stage
- 3.1.4 Factor affecting the value chain
- 3.1.5 Disruptions
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising demand for natural phospholipids
- 3.2.1.2 Increasing nutraceutical and supplement usage
- 3.2.1.3 Expanding pharmaceutical drug delivery applications
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Limited raw material availability from eggs
- 3.2.2.2 Higher cost compared to plant sources
- 3.2.3 Market opportunities
- 3.2.3.1 Growth in clean-label product formulations
- 3.2.3.2 Advancements in liposomal delivery technologies
- 3.2.3.3 Emerging applications in functional food ingredients
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.4.1 North America
- 3.4.2 Europe
- 3.4.3 Asia Pacific
- 3.4.4 Latin America
- 3.4.5 Middle East & Africa
- 3.5 Porter’s analysis
- 3.6 PESTEL analysis
- 3.7 Technology and innovation landscape
- 3.7.1 Current technological trends
- 3.7.2 Emerging technologies
- 3.8 Price trends
- 3.8.1 By region
- 3.8.2 By form
- 3.9 Future market trends
- 3.10 Patent landscape
- 3.11 Trade statistics (HS code)
- 3.11.1 Major importing countries
- 3.11.2 Major exporting countries
- 3.12 Sustainability and environmental aspects
- 3.12.1 Sustainable practices
- 3.12.2 Waste reduction strategies
- 3.12.3 Energy efficiency in production
- 3.12.4 Eco-friendly initiatives
- 3.13 Carbon footprint consideration
Chapter 4 Competitive Landscape, 2025
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.2.1 By region
- 4.2.1.1 North America
- 4.2.1.2 Europe
- 4.2.1.3 Asia Pacific
- 4.2.1.4 LATAM
- 4.2.1.5 MEA
- 4.2.1 By region
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Key developments
- 4.6.1 Mergers & acquisitions
- 4.6.2 Partnerships & collaborations
- 4.6.3 New product launches
- 4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, By Form, 2022-2035 (USD Million) (Kilo Tons)
- 5.1 Key trends
- 5.2 Powder
- 5.3 Liquid
- 5.4 Granule
Chapter 6 Market Estimates and Forecast, By Purity Level, 2022-2035 (USD Million) (Kilo Tons)
- 6.1 Key trends
- 6.2 Food grade (<60% PC)
- 6.3 Cosmetic grade (60-80% PC)
- 6.4 Pharmaceutical grade (≥ 80% PC)
Chapter 7 Market Estimates and Forecast, By Application, 2022-2035 (USD Million) (Kilo Tons)
- 7.1 Key trends
- 7.2 Pharmaceuticals
- 7.3 Nutraceuticals & dietary supplements
- 7.4 Functional food & beverages
- 7.5 Cosmetics & personal care
- 7.6 Others
Chapter 8 Market Estimates and Forecast, By Region, 2022-2035 (USD Million) (Kilo Tons)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 India
- 8.4.3 Japan
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 Lipoid GmbH
- 9.2 VAV Life Sciences Pvt. Ltd.
- 9.3 Avanti Polar Lipids (Croda International)
- 9.4 Phospholipid GmbH
- 9.5 Amadis Chemical Company Limited
- 9.6 American Lecithin Company
- 9.7 Kewpie Corporation
- 9.8 Shaanxi Dideu Medichem Co., Ltd.
- 9.9 Doosan Corporation
- 9.10 Guangzhou Hanfang Pharmaceutical Company Limited
